Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This procedure involves the deposition of beta-emitting yttrium-90 microspheres into the hepatic vasculature to irradiate tumor cells. It is a minimally invasive treatment that combines embolization with radiation therapy to target liver tumors, particularly for inoperable cases. The microspheres emit radiation over a short period, leading to tumor cell death while minimizing damage to surrounding healthy tissue.
Delivery of beta radiation directly to tumors via microspheres. Blocking blood supply to tumors. Inducing cell death in tumor cells while sparing healthy tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor cell irradiation by beta-emitting yttrium-90 microsphere deposition in hepatic vasculature (Y-90 Radioembolization).